Cancer experts hail molecular 'black box'; cancer deaths among Black people fall

The diversity of tumor cells is part of cancer's threat. Now a mouse has been engineered to create an ancestry record in every cancer cell. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      Cancer experts hail a molecular 'black box' that records how cells fly into tumor territory By Angus Chen SAUL LOEB/AFP/Getty Images The diversity of tumor cells is part of cancer's threat. Now a mouse has been engineered to create an ancestry record in every cancer cell. Read More STAT+: 'No real clear path': Insurance coverage for cutting-edge diagnostics remains a major challenge for personalized medicine By Jonathan Wosen Adobe Securing payment for new diagnostics remains a major hurdle to turning personalized medicine’s splashy promises into reality. Read More Cancer deaths among Black people drop, but still higher than other groups By Lindsey Tanner — Associated Press Daniel Linhart/The Virginian-Pilot via AP Cancer deaths have been dropping for all Americans because of lower smoking rates and advances in early detection and treatment. Read More Sponsor content by NATERA How can personalized ctDNA testing enhance surveillance for patients with high risk breast cancer? Personalized testing for circulating tumor DNA (ctDNA) can help catch recurrence early in post-treatment surveillance for high risk breast cancer patients, potentially improving their outcomes. Serial monitoring for presence of ctDNA after primary treatment can inform follow-up care. In a clinical study, a ctDNA assay custom built from each patient's unique tumor detected molecular residual disease (MRD) up to two years ahead of imaging and other indicators. Learn more. National Academies report cites 'urgent' need to recruit more diverse participants for clinical trials By Usha Lee McFarling Adobe The authors said funding to include and recruit more diverse participants for clinical trials should be a priority that is enforced. Read More Tuesday, May 24, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser